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Background: In pulsed-dose rate prostate brachytherapy the dose is delivered during 48 hours after implantation,
making the treatment sensitive to oedematic effects possibly affecting dose delivery. The aim was to study changes
in prostate volume during treatment by analysing catheter configurations on three subsequent scans.
Methods: Prostate expansion was determined for 19 patients from the change in spatial distribution of the
implanted catheters, using three CT-scans: a planning CT (CT1) and two CTs after 24 and 48 hours (CT2, CT3). An
additional 4 patients only received one repeat CT (after 24 hours). The mean radial distance (MRD) of all dwell
positions to the geometric centre of all dwell positions used was calculated to evaluate volume changes. From
three implanted markers changes in inter-marker distances were assessed. The relative shifts of all dwell positions
were determined using catheter- and marker-based registrations. Wilcoxon signed-rank tests were performed to
compare the results from the different time points.
Results: The MRDs measured on the two repeat CTs were significantly different from CT1. The mean prostate volume
change derived from the difference in MRD was +4.3% (range −9.3% to +15.6%) for CT1-CT2 (p < .05) and +4.4%
(range −7.5% to +16.3%) for CT1-CT3 (p < .05). These values represented a mean increase of 1.2 cm3 in the first
24 hours and 1.5 cm3 in the subsequent 24 hours. There was no clear sign of prostate expansion from the change
in inter-marker distance (CT1-CT2: 0.2 ± 1.8 mm; CT1-CT3: 0.6 ± 2.2 mm). Catheter configuration remained stable;
shifts in catheter positions were largest in the C-C direction: 0 ± 1.8 mm for CT1-CT2 and 0 ± 1.4 mm for CT2-CT3.
Conclusions: The volume changes derived from catheter displacements were small and therefore considered
clinically insignificant. Implant configuration remains stable during 2 days of treatment, confirming the safety of
this technique.
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High-dose rate (HDR) brachytherapy combined with ex-
ternal beam radiotherapy (EBRT) is an effective method to
achieve dose escalation in the treatment of localised pros-
tate cancer. It results in increased biochemical relapse-free
survival and reduced acute morbidity, compared with
EBRT alone [1]. An alternative to HDR is pulsed-dose rate
(PDR) brachytherapy, which also exploits the characteris-
tics of local treatment to achieve a conformal high dose to
the prostate [2-4]. The accuracy of dose delivery is an* Correspondence: a.m.dinkla@amc.uva.nl
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unless otherwise stated.important part of a brachytherapy treatment. Inconsisten-
cies or changes in patient and implant geometry between
treatment planning and treatment delivery should be well
documented and eliminated if possible [5].
In low-dose rate (LDR) permanent brachytherapy pros-
tate swelling and accompanying seed movement caused
by oedema plays a major role in the dosimetry. Authors
have measured 20-30% [6-8] up to 50% increase in pros-
tate volume [9]. Oedema arises in the first 24 hours after
implantation after which it slowly resolves [8,9]. If an
HDR treatment is delivered in multiple fractions, vol-
ume changes may occur between these fractions. A PDR
prostate treatment is usually delivered in two days [2,3].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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potentially sensitive to the effects of oedema. Preplan-
ning is done intraoperatively, but the final dose distribu-
tion is planned a few hours after implantation. Volume
changes during implantation therefore do not affect treat-
ment, but volume changes during the treatment can affect
dose delivery.
In HDR treatments, the dose is generally assumed to
be minimally affected by volume changes because the
fraction dose can be delivered in 15 to 20 minutes after
treatment planning [10-12]. Applying more fractions
with the same implant, increases the risk of changes in
dosimetry. Data on prostate volume changes in the first
48 hours after implantation for HDR or PDR brachyther-
apy that support this assumption are sparse. One study
reported data of only 4 patients [13]. Another study found
a large spread in prostate volume changes one week after
HDR treatment, using CT-based prostate delineations
with 5 mm slices [14]. Martinez et al. observed the largest
volume change in the first two scans and negligible
change during the next 32 hours of HDR treatment [12].
Their measurements were based on delineations in axial
transrectal ultrasound (TRUS) images. CT- and TRUS-
based delineations however suffer from contouring un-
certainty of around 2 mm [15]. Kim et al. found a mean
volume increase of 8% 20 hours after implantation using
catheter positions from 3 axial CT slices [16]. Finally,
Kovalchuk et al. measured in 24 patients the prostate
volume change between the first two fractions (sepa-
rated by >6 hours) based on CT delineations, which re-
sulted in a mean absolute change in inter-fractional
volume change of 3.9 cm3 (range −17.7 cm3 to 17.1 cm3)
[17]. The main goal of their study was to measure inter-
fractional needle displacement, which is another factor
that can affect dose coverage. Before delivery of each frac-
tion, they performed needle adjustment to maintain target
coverage. Catheter displacement, usually in craniocaudal
direction, is commonly observed [18,19]. Huang et al.
found that 30% of the catheters needed adjustment to pre-
vent an 8.4% (SD 9.4%) decrease in D90% [18]. Whitaker
et al. found a median measured displacement of 7.5 mm,
with shifts greater than or equal to 5 mm occurring in
67% of their implants, which was corrected for by advan-
cing the source further into the catheters [19]. Milickovic
et al. reported (in all but one case) a maximum needle
movement of less than 1.5 mm [20], which led to a limited
decrease in target coverage. At our institute, self-anchoring
catheters are used to prevent large displacements.
For the PDR prostate patients, the aim was to implant
a minimum number of 12 flexible plastic catheters for
the 48 hour pulsed treatment. A previously published
study on dose variation during these 48 hours showed
only a small decrease in target coverage as compared to the
planning situation: the mean difference in V100% betweenthe planning CT and the scan acquired at the end of the
treatment was only −2.3% with a largest decrease of 10%
[21]. Furthermore, no significant changes in absolute vol-
ume of the delineated prostates were found. However,
prostate delineations suffer from considerable contouring
uncertainty, especially with CT [15,22]. For treatment
planning, both CT, MRI and TRUS can be used [23-25].
The main advantage of MRI is improved soft-tissue con-
trast for prostate boundary detection. With TRUS-based
planning, moving the patient and catheter displacements
are minimized [23,24]. CT is widely available and offers
clear visibility of the catheters. We therefore use the
configuration of the catheters measured on CT as a reli-
able surrogate for volumetric changes. The use of self-
anchoring catheters is to ensure positional stability in
the craniocaudal direction. Since the reports on the
occurrence of oedema during HDR treatment vary
[12-14,16] and no studies have been done for PDR treat-
ments using self-anchoring catheters, our goal was to
study volume changes of the prostate during PDR
brachytherapy by analysing catheter configurations of
subsequent scans acquired throughout the treatment.
Methods
Patients and treatment
Thirty-one prostate cancer patients have been included
in a study to assess the usability of self-anchoring cathe-
ters, of which 23 were eligible for this study. This group
of intermediate- and high-risk patients was treated with
EBRT (23×2 Gy), followed by a PDR boost of 24.96 Gy
[2,26]. The total PDR treatment consisted of 24 pulses,
2.2 hours apart.
Catheter implantation was performed one week after
the end of EBRT according to a pre-plan based on ultra-
sound images. For all patients 12 flexible plastic 6F
self-anchoring catheters were implanted, except for 3
patients, for which 11 catheters were used. The catheters
were placed on the periphery of the prostate to achieve a
high peripheral dose (an example of the implant geom-
etry can be seen in Figure 1). The number of catheters
was independent of prostate volume, which covered a
wide range (21 cm3 to 56 cm3). The implantation pro-
cedure and treatment planning were described previ-
ously [22,26]. No additional fixation of the catheters to
the perineum was applied. During implantation three
fiducial markers were placed in the prostate, two at the
base and one at the apex, to help with the delineation of
these structures on the CT scans. Placement of the
markers was done under ultrasound guidance. The size
of the cylindrical markers was 1 mm in diameter with
5 mm length.
The patient was lying in bed throughout the treat-
ment. To acquire the follow-up CTs, the patients’ bed
was transported from the treatment room to the CT
Figure 1 Example of a transversal prostate image after implantation (CT1, left) and after 48 hours (CT3, right). With the purple dots on
the left image the centre of the catheters are demarcated. A small radial expansion of the catheters can be observed on the right image,
illustrated by the projection of the same dots on this image. The dots were projected by taking the same slice and overlaying the two slices by
matching the urethra and catheters as well as possible.
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with care to avoid implant displacement. Three CT
scans were made for this study. The first CT, which was
used for planning, was acquired after implantation
(CT1, after 1–2 hours), the second CT after 24 hours
(CT2) and the third CT was made after 48 hours, right
before the removal of the catheters (CT3). All scans
were acquired with a resolution of 1 by 1 mm2 pixels
and 2 mm slice thickness. For the first eight patients
that received implantation with self-anchoring cathe-
ters, metal wires had been inserted in the catheters,
which obscured the visibility of the implanted markers.
For this reason these patients were excluded from this
analysis. Of the 23 evaluable patients, 4 did not receive
a third scan.
The catheters were reconstructed manually on all
scans in Oncentra Brachy treatment planning system
(Nucletron, Veenendaal, the Netherlands) by an experi-
enced brachytherapist. Catheter reconstruction was
based on defining 4 to 6 catheter describing points. The
same person also manually defined the position of the
markers on all scans.
Measurement of prostate expansion
Prostate expansion was assessed from the dwell posi-
tions coordinates within the catheters reconstructed on
CT1, CT2 and CT3. The coordinates of dwell positions
inside the catheters are automatically defined by the
software, spaced 5 mm apart. These coordinates were
used as a spatial representation of the catheters, because
of the one-to-one correspondence between these points
on subsequent scans. All dwell positions inside the pros-
tate plus a 5 mm margin were used. Then all coordinates
of these dwell positions were captured scans and the
centre of mass was calculated by taking the mean xand z coordinates (xCOM, zCOM) where x represents the
left-right (L-R) direction and z the dorso-ventral (D-V)
direction. We excluded the y (caudo-cranial, C-C) dir-
ection because any displacement of dwell positions in
this direction represents a catheter shift unrelated to
changes in volume. This is unlike in permanent seed
implantation, where the seed can move in three direc-
tions. Then movement either in cranial or caudal dir-
ection can represent prostate expansion along this
dimension [9].
Subsequently, from the absolute distance between
the centre of mass and every dwell position the





xi−xCOMð Þ2 þ zi−zCOMð Þ2
q
, with n the
number of dwell positions. This calculation was based on
the method of Waterman et al. who assessed volume
changes during permanent implant brachytherapy from
seed positions [9]. Waterman et al. calculated the dis-
placements in all three directions, whereas we excluded
the C-C direction, as was also done by Kim et al. [16]. For
every patient, MRDs were calculated for all three time
points, represented by the three different CT scans.
The relative volume change ΔV(%) was estimated from
the relative change in MRD e.g. between CT1 and CT2
according to the method described by Kim et al. [16]:
ΔV %ð Þ ¼ 100  MRD23−MRD13
MRD13
 
. We estimate the uncer-
tainty in the MRD as follows by first choosing σ = 1 mm
for the uncertainty of the distance between a dwell
position (xi,zi) and the centre of mass (xcom,zcom). The
estimated standard uncertainty in the MRD depends
on the number of dwell positions: σMRD ¼ σ√n . The
number of dwells is on average 80, making σMRD =
1 mm/√80 = 0.1 mm. The propagated uncertainty for
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= 2% (1 SD). For an
MRD1 ≈MRD2 of 15 mm the resulting σDV% is 3% (1SD).
Inter-marker distances
An increase in inter-marker distance between the different
scans indicates the possible presence of oedema. Coordi-
nates of the three implanted markers were recorded for all
CT scans. For each scan, the distance between the three
individual markers was calculated. The three marker pairs
resulted in 3 distances per scan. Since each prostate con-
tained only 3 markers, we did not evaluate the change per
patient. The mean, SD and box-plots of the change in
inter-marker distance (absolute and in the three separate
directions) were calculated for all marker pairs combined.
Dwell position displacement: catheter-based registration
A registration of the catheters reconstructed on subse-
quent scans was performed to evaluate changes in the
catheter configuration. Also here the catheters were repre-
sented by all dwell positions inside the prostate. Displace-
ment of the catheters was measured after aligning the
catheters from subsequent scans, using a rigid registration
of the dwell positions. The corresponding points were
matched using the iterative closest point (ICP) algorithm
[27] as implemented in Matlab (Mathworks, Natick,
Massachusetts). ICP takes two point clouds as input and
returns the rigid transformation (rotation matrix and
translation vector) that best aligns the point clouds. ICP
minimizes the sum of square errors, which is the sum of
squared distances between matched paired points.
This ICP registration of reconstructed catheters was
applied to test if the catheter configuration remained
stable, i.e. whether deformation of the implant had oc-
curred. Measured shifts between CT1-CT2 represented
implant changes in the first 24 hours after implantation.
The shifts between CT2-CT3 represented changes be-
tween 24 and 48 hours. The total shift between CT1-
CT3 was also measured.
To estimate the accuracy of the ICP-based registration,
two CT scans of a fixed 5-catheter configuration inside a
phantom were acquired to register the reconstructed
catheters. The phantom was not rotated or shifted but a
second scan was acquired. The catheters on the two
scans were reconstructed by the same person. Five fea-
ture landmarks inside the phantom were used as marker
surrogates.
Dwell position displacement: marker-based registration
The implanted markers were also used for implant dis-
placement evaluation, since the catheter-based registra-
tion described above is not able to detect entire implantshifts. For this purpose, a marker-based registration was
performed. Because only three markers were implanted,
a quaternion-based method implemented in Matlab was
used for this marker-based registration [28], finding the
rotation and translation that best maps both sets of
marker coordinates in a least squares sense. This rota-
tion and translation was then applied to the catheters to
calculate the dwell position shifts.
The same phantom with fixed catheter configuration
that was used to determine the accuracy of the catheter-
based registration was also used to estimate the accuracy
of the marker-based method.
The marker coordinates have an uncertainty related to
the voxel size. An uncertainty analysis was performed to
quantify the effect of this uncertainty on the accuracy of
marker-based registration of the catheters. A random
noise term was added to the marker coordinates of ten
patients. The coordinates were displaced 100 times with
normally distributed deviations with SDs of 0.5 mm in
the D-V and L-R direction and 1 mm SD in the C-C dir-
ection. These coordinates were registered as above and
these marker-based registrations were applied on the
dwell positions. The mean of all relative displacements
resulted in the uncertainty that can be attributed to the
uncertainty in marker coordinates.
Statistical analysis
The differences in MRDs of subsequent scans as well as
the prostate volumes resulting from these differences
were tested for statistical significance using a Wilcoxon
signed-rank test. P-values below 0.05 were considered
statistically significant. The inter-marker distances mea-
sured on the different scans were also compared using
the Wilcoxon signed-rank test.
Of the calculated dwell position shifts from the
catheter- and marker-based registrations we calculated
for each patient the mean (δ) ± 1 standard deviation
(SD), denoting the random variation per patient (σpat).
The overall mean Δ and the mean standard deviation
(Σ) were calculated. The root-mean-square (RMS) of the
σpat from the 23 patients was calculated to estimate σ,
the overall random variation over all patients. We cre-
ated box-plots containing the interquartile range, me-
dian and minimum and maximum values over all dwell
positions and patients for CT1-CT2 (23 patients), CT2-
CT3 and CT1-CT3 (19 patients). Absolute distances, as
well as shifts in all three directions were assessed.
Results
Measurement of prostate expansion
The MRDs resulted in a statistically significant difference
for MRD1-MRD2 and MRD1-MRD3 (p < .05). The relative
volume change derived from the change in MRD
was +4.3% ± 6.4% (range −9.3% to +15.6%) between
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increase (p < .05). Although statistically significant, this
represented a limited mean volume difference of
1.2 cm3 ± 2.3 cm3 (range −5.2 cm3 to +5 cm3). Taking
the absolute value, the volume change was 6.2% ± 4.4%.
Only for 4 (of 23) patients an increase larger than 10%
was observed. For CT1-CT3, mean volume difference
was +4.4% ± 7.5% (range −7.5% to +16.3%) (p < .05)
(Figure 2). Between CT2-CT3, this was +0.6% ± 3.7%
(range −9.9% to +8.3%) (p > .05). This represented a mean
volume difference of 1.5 cm3 ± 2.8 cm3 (range −4.2 cm3 to
6.2 cm3). In absolute terms, the mean volume change was
6.7% ± 5.4%. For CT2-CT3 it was 2.7% ± 2.6%.
Inter-marker distances
The mean change in inter-marker distance was small in all
three directions (Figure 3). Mean absolute difference was
0.2 ± 1.8 mm (1 SD) between CT1-CT2 and 0.6 ± 2.2 mm
between CT1-CT3. For CT2-CT3, this was 0.4 ± 1.1 mm.
Largest changes were observed in the C-C direction, with
an average increase of 0.6 ± 3.0 mm between CT1-CT3.
The relative change in absolute distance between two
marker pairs was 1.1% ± 7.6% (mean ± 1 SD) between
CT1-CT2 (p > .05), 2.8% ± 9.5% between CT1-CT3 (p < .05)
and 1.5% ± 4.9% between CT2-CT3 (p < .05). So there was
a systematic increase in inter-marker distance of 1.1%-












Figure 2 Relative volume change (%) between CT1-CT2 and between
was omitted, since this information can easily be extrapolated from the othDwell position displacement: catheter-based registration
ICP was first applied to match the catheters inside
the phantom. This catheter registration resulted in a
mean difference between dwell positions of 0.26 ± 0.1 mm
(1 SD).
The relative displacement measured by catheter-based
registration averaged over all dwell positions inside the
catheters of all patients was 1.7 ± 1.2 mm for CT1-CT2
and 1.2 ± 0.9 mm for CT2-CT3. For CT1-CT3 this was
1.6 ± 1 mm. Shifts in the L-R and D-V directions were
small. Catheter shifts in C-C direction were the largest
source of dwell position displacement (Figure 4a).
In Table 1 the mean dwell position shifts are shown, av-
eraged over all patients. The largest mean systematic shift
was −0.22 ± 0.2 mm between CT1-CT3 for the C-C direc-
tion. Random variation, represented by the RMS of all
standard deviations from all patients was in most cases
smaller than 1 mm and largest in the C-C direction.Dwell position displacement: marker-based registration
The registration of the markers coordinates inside the
phantom on two scans resulted in a residual difference
in marker position after registration of 0.1 ± 0.06 mm
(1 SD). The difference in the dwell positions of the cathe-
ters that were subsequently matched according to the




CT1-CT3. For patient 5, 11, 16 and 19, no CT3 was available. CT2-CT3
er two bars.
Figure 3 Boxplots of the change in inter-marker distance. For CT1-CT2, CT2-CT3 and CT1-CT3 the differences in absolute vector length are
shown, as well as for the three separate directions (L-R, C-C and D-V). The dashed horizontal line represents the line of no change in distance
between marker pairs. The boxes itself represent the first and third quartile (lower and upper edge), where the horizontal line inside the box
represents the second quartile, i.e. the median. The crosses represent outliers.
Figure 4 Boxplots of displacements of the dwell positions from catheter-based registration (a) and from marker-based registration (b).
The shifts are shown as absolute vector lengths (abs) and for the three separate directions (L-R, C-C and D-V). For C-C, a positive value indicates a
caudal shift; for D-V, a positive value indicates a ventral shift. The dotted horizontal line represents no displacement. The crosses represent outliers.
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Table 1 Residual distance between dwell positions after catheter-based and marker-based registration, averaged over
all patients
Catheter-based registration Marker-based registration
Mean (mm) 1 SD (mm) RMS of σpat Mean (mm) 1 SD (mm) RMS of σpat
Δ Σ σ Δ Σ σ
CT1-CT2 Absolute 1.67 0.58 1.07 2.46 0.70 1.28
L-R 0.00 0.06 0.64 −0.35 0.45 1.01
C-C* −0.11 0.19 1.72 0.22 1.44 1.83
D-V** −0.01 0.09 0.75 0.01 0.62 1.05
CT1-CT3 Absolute 1.63 0.47 0.94 2.39 0.70 0.95
L-R 0.01 0.04 0.67 −0.15 0.65 0.97
C-C* −0.22 0.20 1.61 −0.05 1.20 1.63
D-V** −0.02 0.06 0.76 0.02 0.71 1.12
CT2-CT3 Absolute 1.21 0.37 0.83 1.91 0.74 1.02
L-R 0.00 0.02 0.46 0.17 0.45 0.72
C-C* −0.05 0.46 1.27 −0.19 1.18 1.46
D-V** −0.01 0.04 0.53 0.05 0.49 0.87
Δ = Overall mean (mean of all δ).
Σ = Standard deviation of the means.
σ = Root-mean-square, quadratic mean of all standard deviations from all patients.
Data shown in absolute shifts and in the 3 separate directions.
*Positive values in C-C indicate a caudal shift.
**Positive values in D-V indicate a ventral shift.
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than the catheter and marker position accuracy.
A separate analysis was performed to quantify the
uncertainty of the measured catheter displacement due
to the uncertainty in marker position. This resulted in
an uncertainty of −0.01 ± 1.1 mm in L-R direction,
0.03 ± 1.4 mm in the C-C direction and 0.02 ± 1.1 mm
in D-V direction.
The relative displacement of all dwell positions mea-
sured by marker-based registration (mean ± 1 SD) was
2.5 ± 1.5 mm for CT1-CT2 and 1.9 ± 1.3 mm for CT2-
CT3 (Figure 4b). For CT1-CT3 this was 2.4 ± 1.2 mm.
In Table 1 the mean dwell position shifts are shown,
averaged over all patients. The largest mean systematic
shift was −0.35 ± 0.45 mm (1 SD) between CT1-CT2 for
the L-R direction. Random variation, represented by the
RMS of all standard deviations from all patients was
around 1 mm and up to 1.8 mm in the y (C-C) direction.
Discussion
This study revealed limited effect of oedema during
48 hours of temporary prostate brachytherapy, with a
maximum increase in prostate volume of 16.3%. We
used catheter positions to quantify volume changes to
eliminate the possible effect of delineation uncertainties.
The catheters are clearly visible, whereas prostate gland
contour delineations on CT are subject to variation
[15,22]. The change in mean radial distance (MRD) be-
tween the dwell positions and the centre of mass ofthe implant resulted in a mean relative volume change
of +4.3% for the first 24 hours and +4.4% for the first
48 hours. With these results the safety of these tech-
niques can be confirmed. Our data supports the conclu-
sion that with PDR and HDR the uncertainties related to
prostate volume changes are small [10,11]. If there was
any oedematic effect from catheter insertion inside the
prostate, it took place in the first 1.5 hours after
implantation.
The mean volume increase in the first 24 hours was
smaller than the 7.8% increase found by Kim et al. mea-
sured on CT after 20 hours [16]. They considered this
clinically insignificant, due to the small change in pros-
tate radius and the limited reduction in target coverage
of around 3%. From their data no relationship between
volume increase (or decrease) and target coverage de-
crease (or increase) could be established. An earlier dosi-
metric analysis of our own patient group showed only a
small decrease in target coverage [21]. Only one patient
showed a large decrease of 7% in V100% on the second
CT-scan and 10% on the third CT-scan. Kim et al. eval-
uated CT-based catheter positions in the L-R and D-V
directions, but looked at the catheter coordinates in just
three axial planes.
The measured volume changes were much smaller
than those reported in LDR series, where expansions of
around 30% was measured [6-8]. In LDR treatments,
more needles are usually implanted and the pre-implant
volume is usually also considered. Furthermore, an LDR
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found a mean increase of even 50% using the mean ra-
dial distance of seeds to the geometric centre of the im-
plant [9]. In our series, some individual cases showed a
volumetric increase of more than 10%, derived from the
MRD. The largest increase in MRD was 0.8 mm, repre-
senting expansions in diameter of 1.6 mm, which could
be considered as a substantial increase. On the other
hand, an example of a patient whose initial prostate vol-
ume was 42 cm3, with a 0.7 mm increase in MRD, is
shown in Figure 1. After the derived 14.7% volume in-
crease the prostate volume would be 48.2 cm3. In line
with Kim et al. [16], it is our conviction that such small
expansions can be considered clinically irrelevant, des-
pite the mean volume increase throughout the treatment
being statistically significant, due to the limited effect on
target coverage.
In this study, isotropic expansion of the prostate was
assumed, although spatial anisotropy of the oedema has
been reported, with average expansions of ∼ 10% in the
D−V and C-C directions and ∼ 0% in the L−R direction
[8]. In this study, the C-C direction was excluded, and
the D-V and L-R directions were assumed equal. Fur-
thermore, in contrast to Kim et al., we did not consider
the expansion in several planes separately to establish
whether or not the prostate expanded isotropically at
the base, middle and apex section of the prostate. They
measured a small but not statistically significant increase
of degree of volume change from apex to base.
Other studies reporting prostate volume changes for
temporary brachytherapy treatments are listed in Table 2.
Kiffer et al. [13] studied changes in implant geometry
between the first and last HDR fraction. By estimating
the cylindrical volume change from D-V and L-R im-
plant coordinates, they found no change in volume in
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Scan times were reported as hours after the first scan, where 0 are the images capt
*Two intervals were studied. Mean is shown for both intervals. Only the range of th
**Two intervals were studied. Mean is shown for both intervals. Only the range of t[14] analysed prostate volumes of a larger patient group
(31 patients) one week after implantation. They observed
a large spread in volumetric changes. However, the de-
termination of these volumes could be impaired by the
relatively large slice thickness in combination with the
delineation uncertainty on CT. In a prospective study on
HDR monotherapy Martinez et al. reported that the vol-
ume increase took place during or shortly after needle
placement [12]. During the subsequent 32–36 hours very
little change in prostate volume occurred, resulting in a
mean D90% decrease of 4%. In our study we used CT in-
stead of axial ultrasound planes and catheter positions
instead of delineations. No CT was made prior to im-
plantation, but the evaluated time span was longer.
A previous study on our data showed that the prostate
volumes of the CT-based prostate delineations did not
vary significantly (Table 2) [21]. The same subset of 23
patients as in the present study had a median change
of +0.6% (range −7.8% to +3.2%) for CT1-CT2 and 0.0%
(range, −7.6% to 9.2%) for CT1-CT3. No statistically
significant correlation was found between the volume
changes in that study and the volume changes derived
from the MRDs. However, those PTVs were based on
CT scans on which the visibility of the prostate boundar-
ies is hampered. Furthermore, the delineations on the
repeat CTs were supported by the delineation of the
planning CT and the fiducial markers. As reported in
the present paper, the distance between the markers can
change up to 7–8 mm, making them less reliable as
landmarks.
The mean inter-marker distances did not change sub-
stantially between subsequent scans. A systematic in-
crease of 1.1%-2.8% was measured, corresponding to an
increase of 0.6 mm. Even though this could indicate a
trend of prostate expansion, the largest marker displace-
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instability of the markers. The markers are implanted
through a needle, creating the possibility to move along
the track left by the needle, before fixating in the gland.
Changes in inter-marker distance were statistically sig-
nificant for CT2-CT3 and CT1-CT3, whereas for the
MRD the changes were statistically significant for CT1-
CT2 and CT1-CT3. To calculate the MRD, catheter dis-
placements of around 80 points in L-R and D-V direction
were used. Inter-marker distances were based on absolute
(3D) vectors between three marker pairs. The uncertainty
in marker position has a much larger effect on this meas-
urement. Besides the difficulty in defining the centre of
the cylindrically shaped 5 mm markers (1 mm diameter),
rotational motion could not be taken into account. Finally,
it is unknown if positional changes whether the positional
changes of the markers are truly caused by changes in
prostate volume or whether another mechanism causes
them to displace.
The average displacements of the dwell positions mea-
sured by catheter-based registration were small, espe-
cially in the L-R and D-V directions, where the mean
shift was 0 mm with a maximum SD of 0.8 mm. We
conclude that the catheter configuration remained
stable throughout the treatment. The C-C direction
showed the largest displacements, with a mean shift of
0 mm ±1.9 mm in the first 24 hours. In the catheter-
based registration, the two reconstructed catheter sets
were aligned as good as possible, thereby possibly com-
pensating for total implant displacement. This also
explained why the measured catheters displacement
between CT1-CT3 were slightly smaller than the sum of
CT1-CT2 and CT2-CT3.
With an average number of 80 dwell positions, the
catheter-based registrations are relatively stable. How-
ever, since that method is not able to detect entire im-
plant shifts, a marker-based registration was performed
as well. The marker-based registration revealed slightly
larger displacements than the catheter-based registra-
tion, also in the C-C direction. This was partly due to in-
accuracy in the marker coordinates (1 mm SD). The
marker-based registration of the phantom images also
resulted in slightly larger shifts than with the catheter-
based registration. Furthermore, the changes in inter-
marker distance revealed instability of the markers,
which also decreases the accuracy of marker-based regis-
tration. Despite the data being slightly more skewed to
caudal displacements, interpretation of the direction of
catheter displacement was therefore somewhat ham-
pered. Note that craniocaudal displacements are unre-
lated to changes in the prostate volume itself, but could
be caused by tissue oedema between the prostatic apex
and the perineum [29]. Peri-prostatic oedema and
oedema in the prostate lateral to the catheters could notbe evaluated with our methods. But since the catheters
were placed on the periphery of the prostate (Figure 1),
we expect to cover the entire prostate volume by analys-
ing volume changes within the catheter space.
Damore et al. studied catheter and marker displace-
ments in the C-C direction on pelvic radiographs [30].
They also note instability of the markers, with a mean
displacement of 3.6 mm. Because of the use of a template,
their catheters shifted as a whole. Catheter displacements
between the first two fractions relative to the pubic sym-
physis (mean 8.3 mm) were larger than relative to the
markers (mean 6.8 mm), which was explained by part of
the motion of the markers and catheters being in the same
direction. The displacement of their needles was larger
than ours, due to the use of a template and smooth stain-
less steel needles, as compared to our self-anchoring nee-
dles. However, they reported that the displacement was
partly overestimated by the use of anterior films that mag-
nify the displacement. Taking two CT-scans spaced
20 hours apart, Kim et al. found an average magnitude of
caudal catheter displacement of 2.7 mm (range −6.0 to
13.5 mm) after bone registration and 5.4 mm (range −3.75
to 18.0 mm) for their marker-based method [31]. They
did not report on the uncertainty of the marker-based
method, but considered the marker-based method to be
more accurate as the prostate can move relative to the
bony anatomy. Foster et al. found comparable cranio-
caudal displacement (mean 5.1 mm) after marker-based
registration between day 1 and day 2 [32].
A previous study on the feasibility of our self-
anchoring catheters showed that the craniocaudal dis-
placement of the tips was minimal [26]: a mean absolute
tip displacement of 1.0 mm (range 0–6 mm) was mea-
sured after marker-based landmark registration of the
two scans. Only the C-C direction was taken into ac-
count. In the current analysis the complete implant con-
figuration in all three directions was evaluated in order
to study volumetric changes of the prostate; however,
the majority of the displacement could still be attributed
to displacements in the C-C direction. The mean absolute
displacements were slightly larger than the previously
measured displacements [26]. Compared to other studies,
the craniocaudal displacements of the self-anchoring cath-
eters were modest [30-32].
Although we consider our method to be accurate, the
accuracy of our method was limited by the accuracy in
catheter reconstruction. The reported accuracy of catheter
reconstruction is 1 mm± 0.5 mm (1 SD) [33], which was
larger than the mean differences between dwell positions
after catheter-based registration. Reconstruction was per-
formed manually on the axial slices and checked on the
reconstructed sagittal view. The diameter of the catheters
was 2 mm and CT pixel size was 0.94 × 0.94 mm2 with a
slice thickness of 2 mm. We use plastic, flexible self-
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ters are usually reconstructed by defining 4 points on axial
planes through the catheters. Others focussed on the
precision of source positioning inside the catheter,
resulting in a standard deviation for source-positioning
offset of ±1.1 mm for PDR afterloaders [34], adding
another small uncertainty to the dose delivery.
In this study we have not studied the effect of changes
in implant geometry on dosimetry. Our results showed
no significant motion in L-R or D-V direction larger
than the reconstruction uncertainty. A study by Pantelis
et al. showed that uncertainties in catheter reconstruc-
tion up to 2 mm and uncertainties in source position of
the order of 1.5 mm along the catheter have no signifi-
cant impact (less than 3%) on the dose-volume histo-
gram (DVH) [35]. We can therefore expect that the
dwell position shifts found in this study also have minor
effect on the dose distribution. Pantelis et al. also con-
cluded that a 4 mm caudal displacement of all catheters
resulted in a D90% decrease of −24%, showing that if the
entire implant shifts the dose coverage is compromised.
Considering that the base of the prostate is often delin-
eated too small on CT [22], caudal displacements of the
catheters are of added concern when it comes to suffi-
cient dose coverage in the base of the prostate. However,
in an earlier study [21] we demonstrated that in our
patient group the mean deviation in prostate V100%
was −3%, making an entire implant shift unlikely
when self-anchoring catheters are used.
Conclusions
Applying four different methods to investigate catheter
geometry changes inside the prostate revealed that both
in the first 24 hours and in the second 24 hours of the
temporary prostate brachytherapy treatment no clinically
relevant volume changes occur that can have significant
impact on dose delivery. Apart from some craniocaudal
displacement, the catheters remain stable during these
2 days of treatment, confirming the safety of this technique.
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